Ionis Pharmaceuticals Inc (IONS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH5161D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

October 2018

Total pages

94

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

Ionis Pharmaceuticals Inc (Ionis) formerly ISIS Pharmaceuticals, Inc. focuses on the discovery and development of RNA-targeted drugs. The company develops first in-class medicines for the treatment of cardiovascular and metabolic disorders, cancer and rare diseases. Ionis develops its products based on its proprietary antisense technology. Its lead product candidates in Phase III development include Kynamro injection being developed in collaboration with Genzyme for the reduction of low-density lipoprotein cholesterol in patients suffering from homozygous familial hypercholesterolemia, or HoFH; Volanesorsen being developed for the treatment of rare, genetic disorders marked by severely high triglyceride levels; IONIS-TTRRx, a first-in-class drug for the treatment of all forms of TTR amyloidosis and Nusinersen being developed for the spinal muscular atrophy (SMA). Ionis is headquartered in Carlsbad, California, the US.

Ionis Pharmaceuticals Inc (IONS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

Ionis Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Ionis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 16

Private Equity 16

Ionis Pharma Recommends Stockholders to Reject Mini-Tender Offer of TRC Capital 16

Partnerships 17

Ionis Pharma Enters into Collaboration Agreement with Roche 17

Cerveau Technologies Enters into Research Agreement with Ionis Pharma 18

SRI International Enters into Reaserch Agreement with Ionis Pharma 19

Biogen and Ionis Pharma Enter into Agreement 20

Biogen and Ionis Pharma Enter into Agreement 21

Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 22

Ionis Pharma Enters into Agreement with Dynacure 24

Ionis Pharma Enters into Agreement with Cystic Fibrosis Foundation 25

Ionis Pharma Partners with University of Texas MD Anderson Cancer Center 26

Biogazelle Enters into Research Agreement with Isis Pharma 27

Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 28

Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders 29

Roche Enters Into Co-Development Agreement With Isis Pharma For Huntington's Disease Treatment 30

AstraZeneca Expands Co-Development Agreement with Isis Pharma 31

Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders 32

Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 33

Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 35

Licensing Agreements 37

PTC Therapeutics Enters into Licesing Agreement with Akcea Therapeutics 37

Akcea Therapeutics Enters into Licensing Agreement with Ionis Pharma 38

AstraZeneca Enters into Licensing Agreement with Ionis Pharma 40

Ionis Pharma Enters into License Agreement with Roche for IONIS-HTTRx 41

Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 42

Ionis Pharma Enters into Licensing Agreement with Dynacure 43

Suzhou Ribo Enters into Licensing Agreement with Ionis Pharma 44

Biogen Exercises Option for Licensing Agreement with Ionis Pharma 45

Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 46

Kastle Therapeutics Acquires Global Rights for KYNAMRO Injection from Ionis Pharma 47

Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 48

Akcea Therapeutics Enters Into Licensing Agreement With Ionis Pharma 49

AstraZeneca Enters into Licensing Agreement with Isis Pharma 51

Bayer HealthCare Amends Licensing Agreement with Ionis Pharma 52

Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 53

Astrazeneca Enters into Licensing Agreement with Isis Pharma 55

Equity Offering 56

Akcea Therapeutics Raises USD143.8 Million in IPO 56

Akcea Therapeutics Raises USD50 Million in Private Placement of Shares 58

Ionis Pharma Files Registration Statement for Public Offering of Shares for up to USD68.7 Million 59

Akcea Therapeutics Raises USD100 Million in Private Placement of Series A Preferred Stock 60

Isis Pharma Completes Public Offering Of Shares For USD 182.7 Million 61

Debt Offering 63

Isis Pharma Completes Private Placement of Notes for USD500 Million 63

Isis Pharma Completes Private Placement Of Convertible Senior Notes Due 2019 For USD 201 Million 65

Ionis Pharmaceuticals Inc-Key Competitors 66

Ionis Pharmaceuticals Inc-Key Employees 67

Ionis Pharmaceuticals Inc-Locations And Subsidiaries 68

Head Office 68

Other Locations & Subsidiaries 68

Joint Venture 69

Recent Developments 70

Financial Announcements 70

Aug 07, 2018: Ionis reports second quarter 2018 financial results 70

May 04, 2018: Ionis Announces First Quarter 2018 Financial Results 73

Feb 27, 2018: Ionis Announces Fourth Quarter and Full Year 2017 Financial Results 76

Nov 07, 2017: Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2017 79

Aug 08, 2017: Ionis Provides Improved 2017 Guidance Following Strong Financial Performance 81

May 09, 2017: Ionis Reports Financial Results and Highlights for First Quarter 2017 83

Feb 28, 2017: Ionis' 2016 Financial Results Outperform Financial Guidance 85

Jan 06, 2017: Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance 89

Corporate Communications 90

Jun 18, 2018: Ionis Pharmaceuticals Names Damien McDevitt As Chief Business Officer 90

Nov 07, 2017: Ionis Announces Management Transitions 91

Sep 24, 2017: Ionis Pharmaceuticals appoints two new board members 92

Other Significant Developments 93

Jun 12, 2018: Akcea and Ambry Genetics to Launch hATTR Compass, a Genetic Testing Program for People with Suspected Hereditary ATTR Amyloidosis 93

Appendix 94

Methodology 94

About GlobalData 94

Contact Us 94

Disclaimer 94


List of Figure

List of Figures

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Ionis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12


List of Table

List of Tables

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Ionis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Ionis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Ionis Pharma Recommends Stockholders to Reject Mini-Tender Offer of TRC Capital 16

Ionis Pharma Enters into Collaboration Agreement with Roche 17

Cerveau Technologies Enters into Research Agreement with Ionis Pharma 18

SRI International Enters into Reaserch Agreement with Ionis Pharma 19

Biogen and Ionis Pharma Enter into Agreement 20

Biogen and Ionis Pharma Enter into Agreement 21

Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 22

Ionis Pharma Enters into Agreement with Dynacure 24

Ionis Pharma Enters into Agreement with Cystic Fibrosis Foundation 25

Ionis Pharma Partners with University of Texas MD Anderson Cancer Center 26

Biogazelle Enters into Research Agreement with Isis Pharma 27

Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 28

Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders 29

Roche Enters Into Co-Development Agreement With Isis Pharma For Huntington's Disease Treatment 30

AstraZeneca Expands Co-Development Agreement with Isis Pharma 31

Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders 32

Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 33

Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 35

PTC Therapeutics Enters into Licesing Agreement with Akcea Therapeutics 37

Akcea Therapeutics Enters into Licensing Agreement with Ionis Pharma 38

AstraZeneca Enters into Licensing Agreement with Ionis Pharma 40

Ionis Pharma Enters into License Agreement with Roche for IONIS-HTTRx 41

Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 42

Ionis Pharma Enters into Licensing Agreement with Dynacure 43

Suzhou Ribo Enters into Licensing Agreement with Ionis Pharma 44

Biogen Exercises Option for Licensing Agreement with Ionis Pharma 45

Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 46

Kastle Therapeutics Acquires Global Rights for KYNAMRO Injection from Ionis Pharma 47

Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 48

Akcea Therapeutics Enters Into Licensing Agreement With Ionis Pharma 49

AstraZeneca Enters into Licensing Agreement with Isis Pharma 51

Bayer HealthCare Amends Licensing Agreement with Ionis Pharma 52

Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 53

Astrazeneca Enters into Licensing Agreement with Isis Pharma 55

Akcea Therapeutics Raises USD143.8 Million in IPO 56

Akcea Therapeutics Raises USD50 Million in Private Placement of Shares 58

Ionis Pharma Files Registration Statement for Public Offering of Shares for up to USD68.7 Million 59

Akcea Therapeutics Raises USD100 Million in Private Placement of Series A Preferred Stock 60

Isis Pharma Completes Public Offering Of Shares For USD 182.7 Million 61

Isis Pharma Completes Private Placement of Notes for USD500 Million 63

Isis Pharma Completes Private Placement Of Convertible Senior Notes Due 2019 For USD 201 Million 65

Ionis Pharmaceuticals Inc, Key Competitors 66

Ionis Pharmaceuticals Inc, Key Employees 67

Ionis Pharmaceuticals Inc, Subsidiaries 68

Ionis Pharmaceuticals Inc, Joint Venture 69

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022